Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.

NCT07343791 is registered in ClinicalTrials.gov with JIANG LONGWEI as lead sponsor.

NCT NCT07343791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07343791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.
Lead sponsor
JIANG LONGWEI
Phase
Phase 1
Overall status
Recruiting
Start date
November 19, 2025
Completion date
November 30, 2027
Enrollment
14 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, dc-cik treatment, immune combination therapy, iparomlimab and tuvonralimab injection, regorafenib